The 21 references in paper N. Avxentyev A., M. Frolov Yu., A. Makarov S., Н. Авксентьев А., М. Фролов Ю., А. Макаров С. (2018) “Фармакоэкономическое исследование применения препарата нилотиниб у больных с хроническим миелоидным лейкозом во второй линии терапии // Pharmacoeconomic analysis of treatment with nilotinib as the second line therapy in patients with chronic myeloid leukemia” / spz:neicon:pharmacoeconomics:y:2018:i:2:p:27-37

1
Turkina A. G., Novitskaya N. V., Golenkov A. K. et al. klinicheskaya onkogematologiya (in Russian). 2017; 10 (3): 390-401.
(check this in PDF content)
2
O’Brien S. G. et al. Imatinib compared with interferon and lowdose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. new england Journal of Medicine. 2003; 348 (11): 9941004.
(check this in PDF content)
3
Cortes J. E. et al. Switching to nilotinib versus imatinib dose escalation in patients with chronic myeloid leukaemia in chronic phase with suboptimal response to imatinib (LASOR): a randomised, openlabel trial. The Lancet Haematology. 2016; 3 (12): e581-e591.
(check this in PDF content)
4
Kantarjian H. et al. Dasatinib or high-dose imatinib for chronic phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily. Cancer. 2009; 115 (18): 4136-4147.
(check this in PDF content)
5
Yagudina R. I., Kulikov A. Yu., Komarov I. A. FARMAkOekOnOMikA. Sovremennaya farmakoekonomika i farmakoepidemiologiya / FARMAkOekOnOMikA. Modern pharmacoeconomics and pharmacoepidemiology (in Russian). 2013; 6: 2.
(check this in PDF content)
6
Kolbin A. S., Frolov M. Yu., Kurylev A. A., Vilyum I. A., Proskurin M. A., Balykina Yu. E. klinicheskaya farmakologiya i terapiya (in Russian). 2015; 2: 91-96.
(check this in PDF content)
7
Serpik V. G. Farmakoekonomika: teoriya i praktika (in Russian). 2015; 3 (2): 8-13.
(check this in PDF content)
8
Omel’yanovskiy V. V., Avksent’eva M. V., Krysanov I. S., Goryaynov S. V., Koval’ D. A. Meditsinskie tekhnologii. Otsenka i vybor (in Russian). 2011; 2: 30-36.
(check this in PDF content)
9
Kantarjian H. M. et al. Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood. 2011; 117 (4): 11411145.
(check this in PDF content)
10
Giles F. J. et al. Nilotinib in imatinib-resistant or imatinibintolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study. Leukemia. 2013; 27 (1): 107-112.
(check this in PDF content)
11
Shah N. P. et al. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinibresistant and-intolerant chronic-phase chronic myeloid leukemia. Journal of Clinical Oncology. 2008; 26 (19): 3204-3212.
(check this in PDF content)
12
Shah N. P. et al. Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib. Haematologica. 2010; 95 (2): 232-240.
(check this in PDF content)
13
Shah N. P. et al. Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study. Blood. 2014; 123 (15): 2317-2324.
(check this in PDF content)
14
Cortes J. E. et al. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome–positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. Blood. 2011; 118 (17): 4567-4576.
(check this in PDF content)
15
Gambacorti-Passerini C. et al. Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up. American Journal of Hematology. 2014; 89 (7): 732-742.
(check this in PDF content)
16
Abdulkadyrov K. M., Turkina A. G., Zaritskiy A. YU., Lomaia E. G. et al. Clinical recommendations for the diagnosis and treatment of chronic myelogenous leukemia. National Hematology Society [klinicheskie rekommendatsii po diagnostike i lecheniyu hronicheskogo mieloleykoza. natsional’noe gematologicheskoe obschestvo (in Russian)]. 2015.
(check this in PDF content)
17
Kantarjian H. et al. Outcome of patients with Philadelphia chromosome positive chronic myelogenous leukemia postimatinib mesylate failure. Cancer. 2007; 109 (8): 1556-1560.
(check this in PDF content)
18
Griffin J. D. et al. Comparing nilotinib with dasatinib as secondline therapies in patients with chronic myelogenous leukemia resistant or intolerant to imatinib–a retrospective chart review analysis. Current medical research and opinion. 2013; 29 (6): 623-631.
(check this in PDF content)
19
Instruktsiya po meditsinskomu primeneniyu lekarstvennogo preparata dlya meditsinskogo primeneniya Tasigna. Gosudarstvennyy reestr lekarstvennyh sredstv Ministerstva zdravoohraneniya RF. [electronic resource] URL: https://grls.rosminzdrav.ru/Grls_View_ v2.aspx?routingGuid=b2c819db-aaf2-43ef-9671-71ecf50a53e1&t=. Accessed: 11.04.2018.
(check this in PDF content)
20
Hughes T. et al. ENESTcmr 4-Year Results: Patients With CMLCP and Residual Disease Are More Likely to Achieve Deep Molecular Response Following Switch to Nilotinib. Haematologica. 2015; 100: [abstract P229].
(check this in PDF content)
21
Hughes T. et al. Treatment free remission (TFR) in patients (pts) with chronic myeloid leukemia in chronic phase (CML CP) treated with second line nilotinib (NIL): First results from the ENESTop study. J Clin Oncol. 2016; 34 (suppl; abstr 7054). Сведения об авторах:
(check this in PDF content)